This suggests simultaneous activation of lipogenesis and lipolysis in the steatotic liver and indicates a protective PPARα function, supported by PPARα KO studies showing the exacerbation of NAFLD progression [49,50] and fenofibrate (PPARα agonist) studies showing reduced steatosis [51,52,53]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.